Physician profile
Patrick Quebedeaux
NPI 1699342725
$979.25
in general payments reported to CMS, 2019-2025
14 companies · $656 in 2025
The $656 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $323 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $301.29 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $120.34 | 2024-2025 | Sogroya |
| Sanofi-Aventis U.S. LLC | $112.33 | 2024-2025 | |
| Dexcom, INC. | $84.97 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $77.39 | 2025 | |
| Ascendis Pharma Endocrinology INC | $74.06 | 2024-2025 | Skytrofa |
| Neurocrine Biosciences, INC. | $48.75 | 2024-2025 | |
| Mannkind Corporation | $33.19 | 2025 | |
| Kyowa Kirin, INC. | $28.42 | 2025 | |
| Endo USA, INC. | $23.67 | 2025 | Supprelin |
| Tolmar, INC. | $20.88 | 2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $19.18 | 2024 | Strensiq |
| Tandem Diabetes Care, INC. | $18.20 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Chiesi USA, INC. | $16.58 | 2025 | Myalept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Quebedeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.